<SEC-DOCUMENT>0001193125-16-776634.txt : 20170306
<SEC-HEADER>0001193125-16-776634.hdr.sgml : 20170306
<ACCEPTANCE-DATETIME>20161123181202
<PRIVATE-TO-PUBLIC>
ACCESSION NUMBER:		0001193125-16-776634
CONFORMED SUBMISSION TYPE:	CORRESP
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20161123

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ARROWHEAD PHARMACEUTICALS, INC.
		CENTRAL INDEX KEY:			0000879407
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				460408024
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		CORRESP

	BUSINESS ADDRESS:	
		STREET 1:		225 SOUTH LAKE AVENUE
		STREET 2:		SUITE 1050
		CITY:			PASADENA
		STATE:			CA
		ZIP:			91101
		BUSINESS PHONE:		626-304-3400

	MAIL ADDRESS:	
		STREET 1:		225 SOUTH LAKE AVENUE
		STREET 2:		SUITE 1050
		CITY:			PASADENA
		STATE:			CA
		ZIP:			91101

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ARROWHEAD RESEARCH CORP
		DATE OF NAME CHANGE:	20040112

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INTERACTIVE GROUP INC
		DATE OF NAME CHANGE:	20020509

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INTERACTIVE INC
		DATE OF NAME CHANGE:	19940224
</SEC-HEADER>
<DOCUMENT>
<TYPE>CORRESP
<SEQUENCE>1
<FILENAME>filename1.htm
<TEXT>
<HTML><HEAD>
<TITLE>CORRESP</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">November&nbsp;23, 2016 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Via EDGAR </U></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Suzanne Hayes </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Assistant Director </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Office of Healthcare and Insurance </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Division of Corporation Finance </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">U.S. Securities and Exchange
Commission </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">100 F Street, NE </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Washington, D.C. 20549-3628
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">Re:</TD>
<TD ALIGN="left" VALIGN="top"><U>Arrowhead Pharmaceuticals, Inc.</U> </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><U>Registration Statement on Form S-3</U> </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><U>Filed October&nbsp;28, 2016</U> </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><U>File No.&nbsp;333-214311</U> </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dear Ms.&nbsp;Hayes: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On behalf of our client, Arrowhead Pharmaceuticals, Inc. (&#147;<I>Arrowhead</I>&#148;), set forth below is Arrowhead&#146;s response to comments of the staff
(the &#147;<I>Staff</I>&#148;) of the U.S. Securities and Exchange Commission (the &#147;<I>Commission</I>&#148;) contained in the comment letter, dated November&nbsp;18, 2016 (the &#147;<I>Comment Letter</I>&#148;), with respect to the above
referenced Registration Statement on Form S-3 (as amended, the &#147;<I>S-3</I>&#148;). On the date hereof, Arrowhead has filed Amendment No.&nbsp;1 to the S-3 (&#147;<I>Amendment No.&nbsp;1</I>&#148;), incorporating the changes described herein.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Exhibit Index </U></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"><I>Please amend your registration statement to file the Common Stock Purchase Agreement with Amgen, Inc. as an exhibit.</I> </TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><U>Response: </U></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Arrowhead
confirms that it has filed the Common Stock Purchase Agreement with Amgen, Inc. as Exhibit 10.1 to Amendment No.&nbsp;1. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"><I>We note that certain of the shares being registered for resale will be issued to Amgen, Inc. upon termination of the applicable waiting period under the HSR Act. Please tell us whether Amgen, Inc. is irrevocably
bound to purchase these shares and whether there are any conditions to closing that are within Amgen, Inc.&#146;s control. Please also confirm that you will not request effectiveness of the registration statement until all conditions to closing are
satisfied or will be satisfied within a short time after effectiveness, including expiration of the HSR waiting period. For guidance, please refer to Question 139.11 of the Securities Act Sections Compliance and Disclosure Interpretations.</I>
</TD></TR></TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g272157001.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">November 23, 2016 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> Page
 2
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><U>Response:</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Arrowhead notes that, as described in Amendment No.&nbsp;1, the applicable waiting period under the HSR Act related to the Amgen, Inc.
transaction has expired, all other conditions to closing have been satisfied, and Amgen, Inc.&#146;s acquisition of the second tranche of Shares, constituting 1,745,810 shares of Arrowhead&#146;s Common Stock, closed on November&nbsp;18, 2016.
Arrowhead further confirms that Amgen, Inc. was irrevocably bound to purchase the Shares that were issued upon the termination of the applicable waiting period under the HSR Act and there were no conditions to closing that were within Amgen,
Inc.&#146;s control. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we can be of any further assistance, or if you have any questions regarding the concerns detailed in this letter, please do not
hesitate to call me at (415)&nbsp;393-8375. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="100%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Sincerely,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">/s/ Ryan A. Murr</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Ryan A. Murr</TD></TR>
</TABLE></DIV> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="5%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="93%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">cc:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Christopher Anzalone</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Chief Executive Officer</I></P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Arrowhead Pharmaceuticals, Inc.</I></P></TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g272157001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g272157001.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    /   _^X #D%D
M;V)E &3      ?_; (0 !@0$! 4$!@4%!@D&!08)"P@&!@@+# H*"PH*#! ,
M# P,# P0# X/$ \.#!,3%!03$QP;&QL<'Q\?'Q\?'Q\?'P$'!P<-# T8$! 8
M&A41%1H?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?
M'Q\?'Q\?'Q\?_\  $0@ &0#+ P$1  (1 0,1 ?_$ )<   (# 0$! 0
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A1"&B$-$(:(0T0AHA#1"&HA#4PAHA#40AJ80T0AHA/__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
